Lionco Pharmaceutical Group Co (SHSE:603669) Cyclically Adjusted Revenue per Share: ¥1.14 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SHSE:603669 Lionco Pharmaceutical Group Co Ltd SHSE:603669
61 GF Score
Price ¥5.55
GF Value ¥7.14
Valuation Modestly Undervalued
! 4 Warning Signs
View Full Analysis

What is Lionco Pharmaceutical Group Co Cyclically Adjusted Revenue per Share?

Lionco Pharmaceutical Group Co SHSE:603669 -0.89% 61 Cyclically Adjusted Revenue per Share is ¥1.14 as of Jun. 2026. GuruFocus rates SHSE:603669 with a GF Score™ of 61/100 and a GF Value™ of ¥7.14 (Modestly Undervalued). The stock has 4 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Lionco Pharmaceutical Group Co's adjusted revenue per share for the three months ended in Jun. 2026 was ¥0.249. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is ¥1.14 for the trailing ten years ended in Jun. 2026.

During the past 12 months, Lionco Pharmaceutical Group Co's average Cyclically Adjusted Revenue Growth Rate was -1.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

As of today (2026-08-25), Lionco Pharmaceutical Group Co's current stock price is ¥5.55. Lionco Pharmaceutical Group Co's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2026 was ¥1.14. Lionco Pharmaceutical Group Co's Cyclically Adjusted PS Ratio of today is 4.87.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Lionco Pharmaceutical Group Co was 7.03. The lowest was 2.61. And the median was 4.03.


Lionco Pharmaceutical Group Co  (SHSE:603669) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Lionco Pharmaceutical Group Co's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=5.55/1.14
=4.87

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Lionco Pharmaceutical Group Co was 7.03. The lowest was 2.61. And the median was 4.03.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Lionco Pharmaceutical Group Co Cyclically Adjusted Revenue per Share Related Terms


Lionco Pharmaceutical Group Co Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Lionco Pharmaceutical Group Co's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Lionco Pharmaceutical Group Co Cyclically Adjusted Revenue per Share Chart

Lionco Pharmaceutical Group Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 1.26 1.19 1.14

Lionco Pharmaceutical Group Co Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.16 1.16 1.14 1.14 1.14

SHSE:603669 vs ZTS: Cyclically Adjusted Revenue per Share Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Lionco Pharmaceutical Group Co's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Lionco Pharmaceutical Group Co Cyclically Adjusted PS Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Lionco Pharmaceutical Group Co's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Lionco Pharmaceutical Group Co's Cyclically Adjusted PS Ratio falls into.


SHSE:603669
61GF Score
Lionco Pharmaceutical Group Co Ltd SHSE:603669
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Lionco Pharmaceutical Group Co Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Lionco Pharmaceutical Group Co's adjusted Revenue per Share data for the three months ended in Jun. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=0.249/116.0564*116.0564
=0.249

Current CPI (Jun. 2026) = 116.0564.

Lionco Pharmaceutical Group Co Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201609 0.161 102.400 0.182
201612 0.217 102.600 0.245
201703 0.172 103.200 0.193
201706 0.287 103.100 0.323
201709 0.329 104.100 0.367
201712 0.562 104.500 0.624
201803 0.458 105.300 0.505
201806 0.730 104.900 0.808
201809 0.511 106.600 0.556
201812 0.670 106.500 0.730
201903 0.505 107.700 0.544
201906 0.640 107.700 0.690
201909 0.545 109.800 0.576
201912 0.583 111.200 0.608
202003 0.354 112.300 0.366
202006 0.328 110.400 0.345
202009 0.428 111.700 0.445
202012 0.265 111.500 0.276
202103 0.390 112.662 0.402
202106 0.247 111.769 0.256
202109 0.210 112.215 0.217
202112 0.111 113.108 0.114
202203 0.184 114.335 0.187
202206 0.099 114.558 0.100
202209 0.078 115.339 0.078
202212 0.047 115.116 0.047
202303 0.096 115.116 0.097
202306 0.063 114.558 0.064
202309 0.045 115.339 0.045
202312 0.070 114.781 0.071
202403 0.096 115.227 0.097
202406 0.119 114.781 0.120
202409 0.110 115.785 0.110
202412 0.201 114.893 0.203
202503 0.069 115.116 0.070
202506 0.172 114.907 0.174
202509 0.150 115.471 0.151
202512 0.058 115.832 0.058
202603 0.120 116.303 0.120
202606 0.249 116.056 0.249

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of ¥1.14 mean?
Lionco Pharmaceutical Group Co (SHSE:603669) has a Cyclically Adjusted Revenue per Share of ¥1.14 as of Jun. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Lionco Pharmaceutical Group Co and its competitors.
Is Lionco Pharmaceutical Group Co's Cyclically Adjusted Revenue per Share too high?
Lionco Pharmaceutical Group Co's current Cyclically Adjusted Revenue per Share is ¥1.14. Overall, Lionco Pharmaceutical Group Co has a GF Score™ of 61/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Lionco Pharmaceutical Group Co's Cyclically Adjusted Revenue per Share compare to ZTS?
Lionco Pharmaceutical Group Co's Cyclically Adjusted Revenue per Share of ¥1.14 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Drug Manufacturers company?
A good Cyclically Adjusted Revenue per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Lionco Pharmaceutical Group Co and its competitors. Lionco Pharmaceutical Group Co's current Cyclically Adjusted Revenue per Share is ¥1.14. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lionco Pharmaceutical Group Co stock overvalued right now?
Based on GuruFocus' analysis, Lionco Pharmaceutical Group Co (SHSE:603669) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥7.14, compared to a current price of ¥5.55 — trading 22.3% below its estimated fair value. The current Cyclically Adjusted Revenue per Share is ¥1.14. Lionco Pharmaceutical Group Co's overall GF Score™ is 61/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Lionco Pharmaceutical Group Co (SHSE:603669), the current Cyclically Adjusted Revenue per Share is ¥1.14 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Lionco Pharmaceutical Group Co (SHSE:603669) Overvalued in 2026?

Based on GuruFocus' analysis, Lionco Pharmaceutical Group Co stock appears to be undervalued. The current stock price of ¥5.55 is trading 22.3% below its estimated GF Value™ of ¥7.14. GuruFocus considers Lionco Pharmaceutical Group Co to be Modestly Undervalued.

Key valuation signals for SHSE:603669:

  • Cyclically Adjusted Revenue per Share: ¥1.14
  • GF Value™: ¥7.14 vs. price of ¥5.55 (22.3% below fair value)
  • GF Score™: 61/100 with 4 warning signs

No single metric tells the full story. See the SHSE:603669 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Lionco Pharmaceutical Group Co Business Description

Address No. 20, National Highway 349, Naidong District, Shannan, CHN
Lionco Pharmaceutical Group Co Ltd is engaged in the research and development of medicines. The product portfolio includes - Alanyl glutamine for injection, fructose for injection, inverted sugar for injection, xylitol for injection, riboflavin sodium phosphate for injection, and water-soluble vitamin for injection.
61GF Score

Get the complete analysis for SHSE:603669

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥5.55
Price
¥7.14
GF Value